Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-05-26

Clinical Trial Update: Clinical Efficacy of Ulinastatin for Treatment of Sepsis With Systemic Inflammatory Response Syndrome [Phase 3]

View source ↗

Summary

Phase 3 clinical trial updating the efficacy of ulinastatin for treatment of sepsis with systemic inflammatory response syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ulinastatin (ulinastatin)

Snippet

Sponsor: Huashan Hospital | Conditions: Sepsis | Phase 3 | Status: UNKNOWN